Medical News / From ASH Meeting 2019, Sutimlimab Improves Hemoglobin in Cold Agglutinin Disease

Investigative therapy sutimlimab provided significant benefit for patients with cold agglutinin disease (CAD) across a series of symptomatic and patient-burden related outcomes, according to new data presented at the American Society of Hematology (ASH) 2019 Annual Meeting in Orlando. Source: MDMag. By reading more or clicking on the link below, you are leaving this site and going to another site run by another organization.

read more

Beaumont Health’s 29th Annual Cardiovascular Conference in Beaver Creek, CO, this February built on its own ... read more
The 29th Annual Beaumont Health Cardiovascular Conference, held in Beaver Creek, CO, provided cardiology investigators and ... read more
Despite the progress made in the fight against cardiovascular disease in recent decades, stroke and mitigating ... read more
There may soon be a cure for sickle cell disease. A team of investigators, led by Erica ... read more